Sector News

Abbott puts one-third of its $6B Mylan stake on the block

March 31, 2015
Life sciences
Abbott Laboratories is selling off one-third of its stake in Mylan, a few weeks after Mylan wrapped up its $5.3 billion stock swap for a portfolio of Abbott’s specialty and branded drugs.
 
Abbott will sell 35 million of the approximately 110 million shares it acquired in that stock swap, about 32% of its stake. The original deal, announced last July, handed Pittsburgh-based generics specialist Mylan a sizable chunk of Abbott’s drug business in developed countries outside the U.S. The portfolio of 100 branded and generic meds brought in $2 billion in 2013 sales, Mylan says.
 
In addition to those drug rights, Mylan gained Abbott’s commercial infrastructure in those markets, which could help it expand sales for its EpiPen injection for anaphylactic shock and launch copies of Teva Pharmaceutical’s multiple sclerosis powerhouse Copaxone and GlaxoSmithKline’s respiratory behemoth Advair, CEO Heather Bresch said at the time of the deal.
 
As part of the stock swap, Mylan and Abbott engineered a tax inversion. The deal created a Netherlands-based operation that would become Mylan’s headquarters for tax purposes. But the two companies had to tweak the terms of the deal after the U.S. Treasury cracked down on companies using M&A to move to tax-friendly countries.
 
The Abbott buy also marked a change of pace for Mylan, which had focused much of its prior dealmaking on emerging markets. The company last year joined forces with Gilead Sciences to roll out HIV drugs in India, launched a biosimilar version of Roche’s blockbuster cancer med Herceptin in that market, and snatched up some Indian plants and development facilities.
 
Mylan in 2013 inked a $1.6 billion deal for India-based Agila Specialties, the injectables unit of Strides Arcolab, picking up a global commercial and manufacturing network to expand the reach for its products.
 
By Emily Wasserman
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).